The Institute of Cancer Research is one of the top-ranked higher education institutions in the world for academic influence and commercial impact, according to an international assessment.

A drug discovered at The Institute of Cancer Research that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust.

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows.